Total Cholesterol
Total Cholesterol
Reagent | Total Cholesterol
Powered by BiozKey Benefits
Exceptional correlation with standard methods
A correlation coefficient of r=0.99 was obtained with a competitor method
Excellent stability
Stable to expiry when stored at 2-8°C
Liquid ready-to-use
The Randox Cholesterol Total reagent is available in a liquid ready to use format for convenience and ease of use.
Other Features
- Liquid ready-to-use reagents
- Correlation coefficient of r=0.99 with competitor method
- Stable to expiry when stored at 2-8°C
| Cat No | Size | ||||
|---|---|---|---|---|---|
| CH200 | 6 x 30ml (S) | Enquire | Kit Insert Request | MSDS | Buy Online |
| CH3810 | 9 x 51ml | Enquire | Kit Insert Request | MSDS | Buy Online |
| CH8019 | 4 x 68ml | Enquire | Kit Insert Request | MSDS | Buy Online |
| CH8310 | 4 x 20ml | Enquire | Kit Insert Request | MSDS | Buy Online |
| (S) Indicates standard included in kit | |||||
Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers. Contact us to enquire about your specific analyser.
What is Total Cholesterol assay used for?
Cholesterol measurements are used in the diagnosis and treatments of lipid lipoprotein metabolism disorders. Lipids play an important role in the body; they serve as hormones or hormone precursors, aid in digestion, provide energy, storage and metabolic fuels, act as functional and structural components in biomembranes and form insulation to allow nerve conduction and prevent heat loss.
In clinical chemistry, over the last decade however, lipids have become associated with lipoprotein metabolism and atherosclerosis.
A patient will be offered a blood cholesterol level test if they:
-
- have been diagnosed with coronary heart disease, stroke or mini-stroke
- are over 40
- have a family history of early cardiovascular disease
- have a close family member who has an inherited cholesterol-related condition
- are overweight or obese
- have high blood pressure or diabetes
- Have another medical condition such as a kidney condition, an underactive thyroid gland or pancreatitis
Publications
- Sajjadi, S.E., et al. Antihyper lipidemic effect of hydroalcoholic extract, and phenolic fraction from Dracocephalum kotschyi Boiss. Pharmaceutica Acta Helvetiae 1998, 73(3): 167-170
- Wallace, J.M.W., et al. Boron supplementation and activated factor VII in healthy men. EJCN 2002, 56(11): 1102-1107
- Joshi, S., et al. Fish oil supplementation of rats during pregnancy reduces adult disease in their offspring. J. Nutr., 2003, 133: 3170-3174
- Ahmed, H.H. and Manna, F. Curcumin as an effective protective agent against ethinylestradiol-induced hepatocellular cholestasis. EGYPT. J. Med. Lab. Sci. 2004, 13(2)
- Ghorbanihaghjo, A., et al. Effect of nandrolone decanoate on serum lipoprotein (a) and its isoforms in hemodialysis patients. Lipids Health Dis. 2004, 3: 16
- Panagia, M., et al. PPAR-α activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am. J. Physiol. Heart Circ. Physiol. 2005, 288: H2677-H2683
- Chen, C-W and Cheng, H-H. A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes. J. Nutr. 2006, 136: 1472-1476
- Macut, G., et al. Oxidised low-density lipoprotein concentration-early marker of an altered lipid metabolism in young women with PCOS. Eur. J. Endocrinol. 2006, 155: 131-136
- Moreira Lima, L., et al. Níveis Plasmàticos Elevados de Lipoproteína(a) Correlacionados com a Gravidade da Doenca Arterial Coronariana em Pacientes Submetidos à Angiografia (Increased Serum Levels of Lipoprotein(a) Correlated with the Severity of Coronary Artery Disease in Patients Submitted to Angiography. Arquivos Brasileiros de Cardiologia. 2006, 87(3): 260-266
- Oyetayo, F.L. Responses of plasma lipids to edible mushroom diets in albino rats. Afr. J. Biotechnol. 2006, 5(13): 1263-1266
- James, A.P., et al. Prior exercise does not affect chylomicron particle number following a mixed meal of moderate fat content. Lipids Health Dis. 2007, 6: 8
- Shen, L., et al. Hypothalamic apolipoprotein A-IV is regulated by leptin. Endocrinology. 2007, 148(6): 2681-2689
- Lawal, H.A., et al. Hypoglycaemic and hypolipidaemic effects of aqueous leaf extract of Murraya koenigii in normal and alloxan-diabetic rats. Nigerian Journal of Physiological Sciences. 2008, 23(1-2): 37-40
- Mineo, D., et al. Effects of lung volume reduction surgery for emphysema on glycolipidic hormones. Chest. 2008, 134(1): 30-37
- Zaragozá, M.C., et al. Toxicity and antioxidant activity in vitro and in vivo of two Fecus vesiculosus extracts. J. Agric. Food. Chem. 2008, 56: 7773-7780
- Bajaj, S., et al. A case-control study on insulin resistance, metabolic co-variates and prediction score in non-alcoholic fatty liver disease. Indian J. Med. Res. 2009, 129: 285-292
- Chou T-W., et al. A Rice bran oil diet improves lipid abnormalities and suppress hyperinsulinemic responses in rats with streptozotocin/nicotinamide-induced Type 2 diabetes. J.Clin. Biochem.Nutr. 2009, 45(1): 29-36
- Hossein-nezhad, A., et al. Association of VDR gene polymorphism with insulin resistance in diabetic patients. Iranian Journal of Diabetes and Lipid Disorders. 2009, 143-150
- Komolafe, O.A., et al. Streptozotocin-induced diabetes alters the serum lipid profiles of adult Wistar rats. The internet Journal of Cardiovascular Research 2009, 7(1) doi: 10.5580/2251
- Lim, W,Y.A., et al. Lipoprotein lipase expression, serum lipid and tissue lipid deposition in orally administered glycyrrhizic acid-treated rats. Lipids in Health and Disease, 2009, 8: 31
- Perše, M., et al. Effect of high-fat mixed-lipid diet and exercise on the antioxidant system in skeletal and cardiac muscles of rats with colon carcinoma. Pharmacol. Rep. 2009, 61(5): 909-916
- Rhodes, P., et al. Adult-onset obesity reveals prenatal programming of glucose-insulin sensitivity in male sheep nutrient restricted during late gestation. PloS ONE 2009, 4(10): e7393
- Velasco-Martínez, R.M., et al. Obesity and insulin resistance among adolescents from Chiapas. Nutr. Hosp. 2009, 24(2)
- Eu, C.H.A., et al. Glycyrrhizic acid improved lipoprotein lipase expression, insulin sensitivity, serum lipid and lipid deposition in high-fat diet-induced obese rats. Lipids and Health Disease. 2010, 9: 81
- Mahadik, S.R. et al. Role of adipocytokines in insulin resistance: Studies from Urban Western Indian Population. Int. J. Diabetes & Metab. 2010, 18(9): 35-42
- Wonnacott, K.E. et al. Dietary omega-3 and-6 polyunsaturated fatty acids affect the composition and development of sheep granulose cells, oocytes and embryos. Reproduction. 2010, 139(1): 57-69
- Kojic, Z., et al. Effect of captopril on serum lipid levels and cardiac mitochondrial oxygen consumption in experimentally-induced hypercholesterolemia in rabbits. Physiol. Res. 2011, 60(1): S177-S184
- Srinivasa, G., et al. Comparison between serum insulin levels and its resistance with biochemical, clinical and anthropometric parameters in South Indian children and adolescents. Ind. J. Biochem. 2011, 26(1): 22-27
- Yahaya, N. et al. Type 2 diabetes with good glycemic control have improved insulin response and lower non-esterified fatty acid level after a meal challenge. Journal of Diabetes Mellitus 2012, 2(1): 1-7
Related Products
Rare Disease Day: 28th February 2019
28th February 2019
Rare Disease Day: 28th February 2019
Rare Disease Day raises awareness of rare diseases and how patients’ lives are affected. Many rare diseases remain incurable and many go undiagnosed. 1 in 20 people will live with a rare disease at some point in their life and this is why it is so important to raise awareness.1
What is a rare disease?
There is no single definition for a rare disease, as many countries identify them differently. In the United States, the Rare Diseases Act of 2002 defines a rare disease by its prevalence: “any disease or condition that affects fewer than 200,000 people in the United States”. However, the EU defines a rare disease as a condition that affects less than 5 in 10,000 of the population. There are approximately 7000 rare diseases and disorders and 50% of people affected by rare diseases are children.2,3
Hyperlipoproteinemia type III
This rare disease day, Randox will be raising awareness of hyperlipoproteinemia type III. Hyperlipoproteinemia type III, also known as dysbetalipoproteinemia or broad beta disease, is a rare genetic disorder characterised by improper breakdown of lipids, specifically cholesterol and triglycerides. The condition is caused by mutations in the Apo-E gene, however the inheritance of this condition is complicated due to the development of symptoms having to be triggered by a secondary factor to raise lipid levels. These factors include diabetes, obesity or hypothyroidism.
It is unknown exactly what the prevalence of the condition is, but it is estimated to affect approximately 1 in 5,000 – 10,000 of the general population and it has been found that it affects males more often than females, with women rarely being affected until after menopause.4,5
Figure A. Example of cholesterol and lipid build-up [6]
Symptoms
Symptoms for hyperlipoproteinemia type III will vary for each individual and some people may even be asymptomatic. The most common symptom is the development of xanthomas which are deposits of fatty material, the lipids, in the skin and underlying tissue. Xanthomas may appear on the palms of the hands, eyelids, soles of the feet or on the tendons of the knees and elbows.
> Chest pain or other signs of coronary artery disease
> Cramps in the calves when walking
> Sores on toes
> Stroke-like symptoms such as trouble speaking, dropping on one side of the face, weakness in an arm or a leg and a loss of balance6
Complications can arise if the condition is left untreated and these can include: myocardial infarction, ischemic stroke, peripheral vascular disease, intermittent claudication and gangrene of the lower extremities.7
Diagnosis
Although there is no specific diagnostic test for hyperlipoproteinemia type III, diagnosis is based on clinical evaluation and identification of symptoms. Research has indicated that an algorithm comprising a number of dysbetalipoproteinemia indices may be helpful in the diagnosis of the disease. These include:
> Low apolipoprotein B to total cholesterol ratio
> Elevated levels of triglycerides
> Elevated levels of total cholesterol8
Managing the condition
The condition cannot be cured but treatment is to control conditions such as obesity, hypothyroidism and diabetes. Most patients will go through dietary therapy to control their intake of cholesterol and saturated fat. This prevents xanthomas, high levels of lipids in the blood, exercise will also help to lower lipid levels. However, dietary changes may not be effective for some individuals and this is where drugs may be used to lower lipid levels instead.
How Randox can Help
Randox offer a range of routine and niche assays within the lipid testing panel to monitor lipid levels and to identify associated complications. Some of these tests include:
Apolipoprotein B
The Randox Apolipoprotein B tests utilises an immunoturbidimetric method, offers a wide measuring range and is available liquid ready-to-use for convenience and ease of use.
Total Cholesterol
The Randox Total Cholesterol test utilises the CHOD-PAP method and offers an extensive measuring range with a wide range of kits available to suit a wide range of laboratory sizes.
Triglycerides
The Randox Triglycerides test utilises the GPO-PAP method while offering an extensive measuring range with both liquid and lyophilised formats available offering choice and flexibility.
Want to know more?
Contact us or download our Cardiology and Lipid Testing brochure to learn more.
Related Products
Randox Reagents
Resource Hub
Lipid Panel Page
References
[1] Rare Disease Day. What is Rare Disease Day? Rare Disease Day. [Online] 2019. [Cited: February 21, 2019.] https://www.rarediseaseday.org/article/what-is-rare-disease-day
[2] Genetic Alliance UK. What is a Rare Disease? Rare Disease UK. [Online] 2018. [Cited: February 21, 2019.] https://www.raredisease.org.uk/what-is-a-rare-disease/
[3] NZORD. Rare Disease Facts and Figures. NZORD. [Online] 2019. [Cited: February 21, 2019.] https://www.nzord.org.nz/helpful-information/rare-disease-facts-and-figures.
[4] NORD. Hyperlipoproteinemia Type III. NORD. [Online] 2019. [Cited: February 21, 2019.] https://rarediseases.org/rare-diseases/hyperlipoproteinemia-type-iii/
[5] GARD. Hyperlipidemia Type 3. National Centre for Advanciing Translational Sciences. [Online] December 29, 2016. [Cited: February 21, 2019.] https://rarediseases.info.nih.gov/diseases/6703/hyperlipidemia-type-3
[6] Falck, Suzanne. Everything you need to know about hyperlipidemia. Medical News Today. [Online] December 21, 2017. [Cited: February 21, 2019.] https://www.medicalnewstoday.com/articles/295385.php
[7] Medline Plus. Familial Dysbetalipoproteinemia. Medline Plus. [Online] May 16, 2018. [Cited: February 21, 2019.] https://medlineplus.gov/ency/article/000402.htm.
[8] Dysbetalipoproteinemia: Two cases report and a diagnostic algorithm. Kei, Anastazia, et al. 4, s.l. : World Journal of Clinical Cases, 2015, Vol. 3.